Top Tech Companies (2,065)
Don't see your company?
Create a company profile
Biosensing platforms that predict the ripeness of fruit, reducing waste and improving produce quality.
Aviara is the development of small molecule integrin inhibitors that modulate the activity.
Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology. By applying these insights, we believe we have a differentiated approach to drug protein targets based on their motion, enabling us to select and advance unique product candidates that can be developed into novel therapies for patients. Located in Cambridge, Massachusetts, our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!
Confluence is a contract research organization providing mechanistic enzymology, target validation, characterization, and more.
Ophirex, Inc., a Public Benefit Corp. focused on treatments for acute, life-threatening illnesses, is modernizing the treatment of snakebite victims by developing an affordable, accessible, oral treatment for immediate use anywhere a snake’s bite occurs. Approximately 80% of the world’s population lives in close proximity to at least one venomous snake species and more than 500,000 people are killed or maimed by snakes each year worldwide.[1][2] Field treatments could help save hundreds of thousands of lives and limbs annually and provide enormous savings in healthcare costs.[2][3] Ophirex is developing a “time of bite” oral snakebite treatment that blocks the most commonly lethal component of snake venom—present in 95% of the world’s venomous snakes.[4] This antidote—now in human clinical trials—can be administered immediately in the field or in the hospital to effectively stop the venom’s devastating assault.[5][6][7] 1. Vulnerability to snakebite envenoming: a global mapping of hotspots. www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31224-8/fulltext 2. Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. https://doi.org/10.1371/journal.pntd.0007059 3. Snakebite: An Exploratory Cost-Effectiveness Analysis of Adjunct Treatment Strategies. www.ajtmh.org/view/journals/tpmd/99/2/article-p404.xml 4. A Review and Database of Snake Venom Proteomes. https://pubmed.ncbi.nlm.nih.gov/28927001/ 5. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. https://pubmed.ncbi.nlm.nih.gov/27571102/ 6. Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms. www.ncbi.nlm.nih.gov/pmc/articles/PMC7076770/ 7. Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (BRAVO). https://clinicaltrials.gov/ct2/show/NCT04996264
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
Myosana Therapeutics, Inc. is pioneering efforts in developing non-viral targeted gene therapy for skeletal muscle and cardiac diseases. Our current focus is Duchenne muscular dystrophy (DMD) but our platform is applicable to any genetic muscle disease. Current gene therapy for skeletal and cardiac muscle diseases uses Adeno Associated Virus (AAV) to deliver small healthy genes or portions of large genes, to the cells that contain unhealthy (mutated) genes. AAV has numerous limitations, including limited gene size capacity (5 kilobases), precluding its use for many larger genes like dystrophin. Furthermore, many individuals may have naturally occurring antibodies against AAV or will develop antibodies after their first treatment, limiting treatment to a single dose. The Myosana Platform Technology bypasses the limitations of AAV delivery and, therefore, is much more versatile. • The Myosana platform does not use viruses to deliver genes to the cells. • The new technology can deliver genes of any size. • The Myosana Non-Viral delivery method is much less likely to elicit an immune response, enabling repeated dosing over months or years. • The Myosana platform targets the healthy gene to skeletal and cardiac muscle cells. The novel gene therapy approach we have developed will provide new treatments for many diseases of skeletal and cardiac muscle. Our current focus is DMD, but we expect to use the platform to treat other muscular dystrophies and congenital myopathies.
CharlestonPharma is focused on developing innovative therapeutic antibodies and related diagnostic tests for cancer patients.
iCarbonX is a technology company that is changing how people monitor and understand their health status and optimize their lives. We are building the platform and tools for digitizing, analyzing, and understanding life, and delivering intelligent products and applications—designed for every aspect and stage of life—to help everyone make smarter choices, every day. We’re inspired by every life on this planet, and by a commitment to apply intelligence not just to data, but to the ethical use of that data. Our mission is to bring people together to improve the human condition. We believe we must go beyond genetics to help people understand not just who they are, but how they are. We’re answering the “how” by combining biological and behavioral data with artificial intelligence in a network where people can learn from their own experience and from others like them, creating a global map of human health across cultures and continents that delivers new information and new choices, for life.
Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don’t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
BrightSpec is an innovative life science tools company with a range of instruments that tap the power of molecular rotational resonance (MRR) spectroscopy. MRR enables the rapid, unambiguous molecular ID and quantitative analysis of mixtures, without separation, no chemometrics, and with no reference sample required. Not only can BrightSpec MRR complement other techniques such as Mass Spectrometry or NMR, in many cases MRR can solve problems not possible by these methods. For instance, MRR can easily distinguish between isomers (compounds with the same atoms but a different arrangement) or identify the exact site of deuteration of a molecule as well as quantify the number of each in the sample. BrightSpec is in the process of working with leading pharma, biotech, and academic players to develop breakthrough methods that will enable important advances in discovery. The company is also working with major chemical, oil & gas, consumer products, security, and environmental players to bring innovative solutions to these applied markets. The work is supported by research from a growing number of academic institutions as evidenced by a rising number of publications using BrightSpec instruments. BrightSpec builds on decades of federal and academic work in more than 110 research groups around the world. The technique was developed foremost in astrochemistry research. Using breakthrough technology developed by Brooks Pate at the University of Virginia, BrightSpec made this powerful technique of practical use by making the instrument significantly faster, cheaper, and easier to use. MRR spectra capture the unique set of rotational resonances, a fingerprint specific to a given molecular structure. These can be calculated theoretically based on quantum mechanics and are highly resolved. Isomers, isotopologues, diastereomers and enantiomers can be distinctly identified.
From Discovery to Delivery™, Azzur Group provides the life science community with full lifecycle solutions for all their GxP needs. From Azzur Cleanrooms on Demand™ facilities, to labs, training centers, and consulting and advisory offices across the nation, Azzur helps organizations start, scale, and sustain their enterprises. With four decades of service to the industry, we've become a trusted partner to leading pharmaceutical, biotechnology, medical device, and healthcare companies, as well as their supply chain.
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.
Hesperos, Inc. is accelerating drug discovery by providing safety and efficacy testing of chemicals and novel therapeutics for the pharmaceutical, cosmetic, and food industries using its patented, Human-on-a-Chip platform. Bringing together biologists, surface chemists, and engineers, our team is producing some of the world's most advanced organs-on-a-chip platforms. From gene expression to electrophysiology, we recreate key components of organs in an interconnected, functional system. Chemically patterned microchips enable real-time, non-invasive monitoring of organ function where we use sophisticated measurement techniques to detect minute changes. This breakthrough technology enables unprecedented visibility into specific disease states and how the human body will respond to treatment - something that previously required costly animal testing and human trials to determine. The functional, interconnected, human in vitro platform, provides preclinical insight into the efficacy and toxicity of novel therapeutics. Ultimately, Hesperos’ Human-on-a-Chip is reducing the need for animal testing in drug discovery while enabling research into rare diseases previously considered untreatable.
A clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including neurodegenerative diseases, cancer and autoimmune disorders.
Innovative C# development
Recros Medica is a medical device company developing technologies to treat skin laxity and focal aesthetic contour deformities.
Sirion Therapeutics is a biopharmaceutical company, engaged in developing, and commercializing of products for the protection of eyesight.
We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Vistim Labs is medtech diagnostic helping pharma detect, treat, and track neurological disorders. We offer a brain scan for high precision measurement of cognition function and treatment efficacy. Our mission is to accelerate access to care by improving clinical decision making ability with our proprietary artificial intelligence platform. Our biomarkers of cognitive decline are useful for predicting symptomatic onset of disease and for measuring efficacy of treatment for emerging interventions. In this way, patients receive the most effective treatments available and quality of life is protected.
